-
1.发明申请MODIFIED TOBACCO MOSAIC VIRUS PARTICLES AS SCAFFOLDS FOR DISPLAY OF PROTEIN ANTIGENS FOR VACCINE APPLICATIONS 审中-公开作为疫苗显示用于疫苗应用的蛋白质抗原的改良烟草马赛克病毒颗粒
公开(公告)号：WO2007038145A3
公开(公告)日：2007-10-11
申请号：PCT/US2006036668
申请日：2006-09-08
Applicant: LARGE SCALE BIOLOGY CORP
Inventor： LINDBO JOHN A , SMITH MARK L , PALMER KENNETH E
IPC: C12N7/01
CPC classification number: C07K14/005 , A61K39/12 , A61K39/21 , A61K39/385 , A61K2039/5258 , A61K2039/55566 , A61K2039/6075 , A61K2039/625 , C07K2319/00 , C07K2319/22 , C07K2319/60 , C12N7/00 , C12N15/8203 , C12N15/8257 , C12N15/8258 , C12N2710/20022 , C12N2710/20023 , C12N2710/20034 , C12N2740/16122 , C12N2740/16134 , C12N2770/00022
Abstract: Compositions and methods to utilize coat proteins of tobacco mosaic virus (TMV) as a scaffold with commonly available linker chemistries and surface antigens to enhance immune responses when used as a vaccination; randomized library to introduce a reactive lysine or cysteine residue externally located at the amino-terminus of the coat protein. TMV coat protein modification allows a controlled stoichiometric biotinylation of the Introduced lysine or cysteine residues further allowing the attachment of antigens using streptavidin as a linker to the biotinylated coat protein. A TMV-protein complex vaccine prepared utilizing this invention results in enhanced immunogenicity and a detectable humoral immune response after only a single immunization in mice.
Abstract translation: 使用烟草花叶病毒（TMV）的外壳蛋白作为具有通常可用的接头化学物质和表面抗原的支架的组合物和方法，以在用作疫苗接种时增强免疫应答; 随机化文库引入外部位于外壳蛋白的氨基末端的反应性赖氨酸或半胱氨酸残基。 TMV外壳蛋白修饰允许引入的赖氨酸或半胱氨酸残基的受控化学计量生物素化进一步允许使用链霉抗生物素蛋白作为接头与生物素化的外壳蛋白连接抗原。 使用本发明制备的TMV-蛋白复合疫苗在小鼠中仅进行单次免疫后导致增强的免疫原性和可检测的体液免疫应答。
-
公开(公告)号：WO2005091753A3
公开(公告)日：2006-08-03
申请号：PCT/US2005010191
申请日：2005-03-25
Applicant: LARGE SCALE BIOLOGY CORP , MCCORMICK ALISON A , SMITH MARK L , PALMER KENNETH E , LINDBO JOHN A , NGUYEN LONG V , POGUE GREGORY P
Inventor： MCCORMICK ALISON A , SMITH MARK L , PALMER KENNETH E , LINDBO JOHN A , NGUYEN LONG V , POGUE GREGORY P
IPC: A61K48/00 , A61K39/385 , A61K47/48 , C07K14/025 , C07K14/08 , C07K14/11 , C07K14/12 , C07K14/16 , C07K14/47 , C12N7/04
CPC classification number: C07K14/005 , A61K39/385 , A61K47/646 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , A61K2039/545 , A61K2039/6075 , A61K2039/62 , A61K2039/627 , A61K2039/64 , C07K14/4748 , C07K2319/00 , C12N7/00 , C12N2710/20022 , C12N2710/20023 , C12N2740/16122 , C12N2760/16122 , C12N2760/18422 , C12N2770/00022 , C12N2770/36143
Abstract: Herein described are various methods for making a vaccine that are made of reassembled virus like particles (VLP). First, the VLPs are disassembled into coat proteins or encapsidation intermediate populations. Each population undergoes, for instance, chemical conjugation of unique peptide or nucleic moieties to form separate populations. Thereafter, a predetermined amount of each of the several (one or more) different coat proteins or encapsidation intermediates from the different populations is mixed and joined, forming intact VLPs, surrounding a nucleic acid core, that are composed of different coat proteins such that the reassembled VLP displays more than one peptide or other molecule. The nucleic acid can function either as a scaffold alone or can be engineered for the expression of an immunomodulatory protein in a eukaryotic cell.
Abstract translation: 本文描述了制备由重组病毒样颗粒（VLP）制成的疫苗的各种方法。 首先，将VLP分解成外壳蛋白或衣壳化中间种群。 每个群体经历例如独特的肽或核酸部分的化学共轭以形成分开的群体。 此后，将来自不同群体的几种（一种或多种）不同外壳蛋白或壳化中间体中的每一种的预定量混合并结合，形成由不同外壳蛋白构成的核酸核心周围的完整VLP， 重组VLP显示多于一个肽或其他分子。 核酸可以作为单独的支架起作用，或者可以被工程化以在真核细胞中表达免疫调节蛋白。
-
公开(公告)号：WO0161024A3
公开(公告)日：2002-06-27
申请号：PCT/US0105394
申请日：2001-02-15
Applicant: LARGE SCALE BIOLOGY CORP , PALMER KENNETH E , POGUE GREGORY P
Inventor： PALMER KENNETH E , POGUE GREGORY P
CPC classification number: C07K14/005 , A01K2217/05 , C12N15/79 , C12N15/86 , C12N2750/00022 , C12N2750/12043 , C12N2800/108 , C12N2830/42
Abstract: A rolling circle DNA replicon which replicates in a host eukaryotic cell is disclosed which has a truncated replication cycle. The rolling circle DNA replicon comprises the following elements present on the same DNA molecule. It contains a Rep gene open reading frame from a virus belonging to the viral taxonomic families Geminiviridae, Circoviridae or genus Nanovirus . The Rep gene open reading frame is placed under transcriptional control of a promoter, which is placed 5' of the gene. Any sequences that are required to be present in cis on the rolling circle DNA replicon in order that the Rep protein might promote replication of the rolling circle DNA replicon are included. An expression cassette for expression of an ancillary protein that is capable of creating a cellular environment permissive for replication of the rolling circle DNA replicon in the host cell of interest is also included. At least one expression cassette with an RNA polymerase II promoter, a multiple cloning site, and transcription termination and polyadenylation signals suitable for transcription of RNA molecules not normally intrinsic to a geminiviral, circoviral or nanoviral genome is also included.
Abstract translation: 公开了在宿主真核细胞中复制的旋环DNA复制子，其具有截短的复制周期。 滚环DNA复制子包含存在于相同DNA分子上的以下元素。 它包含来自属于病毒分类学家Geminiviridae，Circoviridae或属Nanovirus的病毒的Rep基因开放阅读框。 将Rep基因开放阅读框置于启动子的转录控制下，其位于基因的5'。 包括在循环DNA复制子上需要存在于顺式中的任何序列，以使Rep蛋白可能促进滚环DNA复制子的复制。 还包括用于表达能够产生在感兴趣的宿主细胞中允许循环DNA复制子复制的细胞环境的辅助蛋白质的表达盒。 还包括至少一个具有RNA聚合酶II启动子，多克隆位点和适合于双因素病毒，环状病毒或纳米病毒基因组通常不固有的RNA分子转录的转录终止和多聚腺苷酸化信号的表达盒。
-
公开(公告)号：WO2004032622A8
公开(公告)日：2007-11-01
申请号：PCT/US0327563
申请日：2003-09-03
Applicant: LARGE SCALE BIOLOGY CORP
Inventor： PALMER KENNETH E , TOTH RACHEL L , JONES MICHAEL , CHAPMAN SEAN , SMOLENSKA LISA , MCCORMICK ALISON , POGUE GREGORY , NGUYEN LONG
IPC: A61K39/00 , A01N20060101 , A01N1/00 , A01N61/00 , A61K38/12 , A61K39/12 , A61K48/00 , A61P31/12 , C07K16/08 , C12N7/00 , G01N33/569
CPC classification number: C07K14/005 , A61K39/12 , A61K39/21 , A61K39/23 , A61K2039/5256 , A61K2039/5258 , A61K2039/545 , C12N7/00 , C12N2710/20022 , C12N2710/20034 , C12N2740/16134 , C12N2740/16334 , C12N2750/14334 , C12N2760/12222
Abstract: Vaccines and diagnostic composition are made and used for preventing, treating and detecting antigens from a papilloma virus, ebola virus, HIV virus, Rift Valley Fever virus or a parvovirus. The epitopes of these viruses are produced as genetically engineered fusion peptides in plants by infection with a recombinant tobamovirus vectors to express fusion proteins containing the epitope peptides.
Abstract translation: 疫苗和诊断组合物被制备并用于预防，治疗和检测来自乳头瘤病毒，埃博拉病毒，HIV病毒，裂谷热病毒或细小病毒的抗原。 这些病毒的表位通过用重组烟草花叶病毒载体感染来表达含有表位肽的融合蛋白，作为遗传工程改造的融合肽在植物中产生。
-
Patent Agency Ranking
公开(公告)号：WO2004032622A2
公开(公告)日：2004-04-22
申请号：PCT/US0327563
申请日：2003-09-03
Applicant: LARGE SCALE BIOLOGY CORP
Inventor： PALMER KENNETH E , TOTH RACHEL L , JONES MICHAEL , CHAPMAN SEAN , SMOLENSKA LISA , MCCORMICK ALISON , POGUE GREGORY , NGUYEN LONG
IPC: A01N20060101 , A01N1/00 , A61K39/12 , A61K48/00 , A61P31/12 , C07K16/08 , C12N7/00 , G01N33/569 , A01N
CPC classification number: C07K14/005 , A61K39/12 , A61K39/21 , A61K39/23 , A61K2039/5256 , A61K2039/5258 , A61K2039/545 , C12N7/00 , C12N2710/20022 , C12N2710/20034 , C12N2740/16134 , C12N2740/16334 , C12N2750/14334 , C12N2760/12222
Abstract: Vaccines and diagnostic composition are made and used for preventing, treating and detecting antigens from a papilloma virus, ebola virus, HIV virus, Rift Valley Fever virus or a parvovirus. The epitopes of these viruses are produced as genetically engineered fusion peptides in plants by infection with a recombinant tobamovirus vectors to express fusion proteins containing the epitope peptides.
Abstract translation: 疫苗和诊断组合物被制备并用于预防，治疗和检测来自乳头瘤病毒，埃博拉病毒，HIV病毒，裂谷热病毒或细小病毒的抗原。 这些病毒的表位通过用重组烟草花叶病毒载体感染来表达含有表位肽的融合蛋白，作为遗传工程改造的融合肽在植物中产生。
-
公开(公告)号：WO2006042327A3
公开(公告)日：2009-04-16
申请号：PCT/US2005037097
申请日：2005-10-12
Applicant: LARGE SCALE BIOLOGY CORP , VOJDANI FAKHRIEH S , PALMER KENNETH E , GARGER STEPHEN J , POGUE GREGORY P
Inventor： VOJDANI FAKHRIEH S , PALMER KENNETH E , GARGER STEPHEN J , POGUE GREGORY P
CPC classification number: C12N15/8257 , C07K14/8117
Abstract: The present invention relates to plant produced native aprotinin and aprotinin variants having enzyme-inhibitory, immunological and pharmacokinetic properties and their preparation. In a preferred method a recombinant RNA plant virus is used to express native aprotinin + variants thereof in Nicotiana plants.
Abstract translation: 本发明涉及具有酶抑制，免疫学和药代动力学性质及其制备的植物产生的天然抑肽酶和抑肽酶变体。 在优选的方法中，重组RNA植物病毒用于在烟草属植物中表达天然抑肽酶+变体。
-
公开(公告)号：WO2005108564A2
公开(公告)日：2005-11-17
申请号：PCT/US2005010192
申请日：2005-03-25
Applicant: LARGE SCALE BIOLOGY CORP , PALMER KENNETH E , TOTH RACHEL L , JONES MIKE , CHAPMAN SEAN , SMOLENSKA LISA , MCCORMICK ALISON A , POGUE GREGORY P , NGUYEN LONG V
Inventor： PALMER KENNETH E , TOTH RACHEL L , JONES MIKE , CHAPMAN SEAN , SMOLENSKA LISA , MCCORMICK ALISON A , POGUE GREGORY P , NGUYEN LONG V
CPC classification number: C12N15/8257 , A61K2039/5256 , A61K2039/6075 , C12N15/8258 , C12N2710/20022 , C12N2740/15022 , C12N2740/16022 , C12N2750/14322 , C12N2760/12222 , C12N2760/14122
Abstract: Vaccines and diagnostic composition are made and used for preventing, treating and detecting antigens from a papilloma virus, ebola virus, HIV virus, Rift Valley Fever virus or a parvovirus. The epitopes of these viruses are produced as genetically engineered fusion peptides in plants by infection with a recombinant tobamovirus vectors to express fusion proteins containing the epitope peptides.
Abstract translation: 疫苗和诊断组合物被制备并用于预防，治疗和检测来自乳头瘤病毒，埃博拉病毒，HIV病毒，裂谷热病毒或细小病毒的抗原。 这些病毒的表位通过用重组烟草花叶病毒载体感染来表达含有表位肽的融合蛋白，作为遗传工程改造的融合肽在植物中产生。
-
公开(公告)号：WO03103605A2
公开(公告)日：2003-12-18
申请号：PCT/US0318247
申请日：2003-06-06
Applicant: LARGE SCALE BIOLOGY CORP
Inventor： MCCORMICK ALISON A , SMITH MARK L , PALMER KENNETH E , LINDBO JOHN A , NGUYEN LONG V , POGUE GREGORY P
IPC: A61K20060101 , A61K39/12 , A61K39/385 , A61K48/00 , C07K14/025 , C07K14/08 , C07K14/11 , C07K14/115 , C07K14/12 , C07K14/47 , C07K19/00 , C12N7/00 , C12N7/01 , C12N7/04 , C12N15/86 , A61K
CPC classification number: C07K14/005 , A61K39/0011 , A61K39/12 , A61K39/385 , A61K2039/5258 , A61K2039/55516 , A61K2039/6075 , A61K2039/627 , A61K2039/64 , C07K14/4748 , C07K2319/00 , C12N7/00 , C12N2710/20022 , C12N2710/20034 , C12N2760/16122 , C12N2760/18022 , C12N2770/00022 , C12N2770/00023
Abstract: Herein described are various methods for making a vaccine that are made of re-assembled virus like particles (VLP). First, the VLPs are disassembled into encapsidation intermediate populations. Each encapsidation intermediate population undergoes, for instance, chemical conjugation of unique peptide or nucleic moieties to form separate populations. Thereafter, a predetermined amount of each of the several (one or more) different encapsidation intermediates from the different populations is mixed and joined, forming intact VLPs, surrounding a nucleic acid core, that are composed of different encapsidation intermediate such that the reassembled VLP displays more than one peptide or nucleic acid. The nucleic acid can function either as a scaffold alone or can be engineered for the expression of an immunomodulatory protein in a eukaryotic cell.
Abstract translation: 本文描述了制备由重新组装的病毒样颗粒（VLP）制成的疫苗的各种方法。 首先，将VLP分解成壳化中间种群。 每个壳化中间体经历例如独特的肽或核酸部分的化学共轭以形成分开的群体。 此后，将来自不同群体的几种（一种或多种）不同的壳化中间体中的每一种的预定量混合并连接，形成围绕核酸核心的完整的VLP，其由不同的包封中间体组成，使得重新组装的VLP显示 多于一种肽或核酸。 核酸可以作为单独的支架起作用，或者可以被工程化以在真核细胞中表达免疫调节蛋白。
-
公开(公告)号：WO0177350A3
公开(公告)日：2002-08-08
申请号：PCT/US0111436
申请日：2001-04-04
Applicant: LARGE SCALE BIOLOGY CORP , PALMER KENNETH E , POGUE GREGORY P
Inventor： PALMER KENNETH E , POGUE GREGORY P
IPC: C12N15/79
CPC classification number: C12N15/79
Abstract: The present invention provides an eukaryotic recombinant vector suited for bi-directional transcription of a transgene to yield both sense and antisense RNA transcripts of the transgene in an eukaryotic cell. The invention vectors are particularly suited for mediating gene silencing in a variety of biological systems. The present invention also provides host cells and transgenic plants comprising the invention vectors. Further provided by the invention are methods of inhibiting expression of an endogenous gene present in an eukaryotic cell. Also included is a method of identifying a biological function(s) of an endogenous gene of interest in an eukaryotic cell by selectively inhibiting the expression of the endogenous gene.
Abstract translation: 本发明提供了适用于转基因双向转录的真核重组载体，以产生真核细胞中转基因的有义和反义RNA转录物。 本发明载体特别适用于介导各种生物系统中的基因沉默。 本发明还提供宿主细胞和包含本发明载体的转基因植物。 本发明进一步提供的是抑制存在于真核细胞中的内源基因表达的方法。 还包括通过选择性抑制内源基因的表达来鉴定真核细胞中感兴趣的内源基因的生物学功能的方法。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.026 seconds)
